Clinical Trials Directory

Trials / Completed

CompletedNCT00631358

Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
97 (actual)
Sponsor
Alcon Research · Industry
Sex
All
Age
17 Years
Healthy volunteers
Accepted

Summary

The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.

Conditions

Interventions

TypeNameDescription
DRUGMaxidexMaxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
OTHERNo treatmentHealthy normal control group receiving no treatment

Timeline

Start date
2008-02-01
Primary completion
2009-02-01
First posted
2008-03-07
Last updated
2010-04-12
Results posted
2010-04-12

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT00631358. Inclusion in this directory is not an endorsement.